![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, May 25, 2011 3:36:08 AM
http://www.insidercow.com/
S 2010-12-17 2010-12-21 15:23:22 DISCOVERY LABORATORIES INC /DE/ DSCO LOPEZ DAVID L officer (Executive VP & Legal Counsel) 16,300 $0.21 $3,449.08 261,834 N/A view
S 2010-12-17 2010-12-21 15:23:22 DISCOVERY LABORATORIES INC /DE/ DSCO LOPEZ DAVID L officer (Executive VP & Legal Counsel) 700 $0.21 $148.47 278,134 N/A view
P 2008-11-20 2008-11-20 13:07:48 DISCOVERY LABORATORIES INC /DE/ DSCO ROSENTHALE MARVIN E director 14,674 $0.89 $13,133.20 225,000 32.96% view
P 2008-11-19 2008-11-20 13:07:48 DISCOVERY LABORATORIES INC /DE/ DSCO ROSENTHALE MARVIN E director 9,655 $0.93 $8,979.15 210,326 27.96% view
P 2008-11-18 2008-11-20 13:07:48 DISCOVERY LABORATORIES INC /DE/ DSCO ROSENTHALE MARVIN E director 25,671 $1.00 $25,671.00 200,671 17.00% view
P 2008-11-20 2008-11-20 13:07:48 DISCOVERY LABORATORIES INC /DE/ DSCO ROSENTHALE MARVIN E director 500 $0.91 $453.00 125,000 31.35% view
P 2008-11-19 2008-11-20 13:07:48 DISCOVERY LABORATORIES INC /DE/ DSCO ROSENTHALE MARVIN E director 23,400 $0.93 $21,762.00 124,500 27.96% view
P 2008-11-18 2008-11-20 13:07:48 DISCOVERY LABORATORIES INC /DE/ DSCO ROSENTHALE MARVIN E director 1,100 $1.00 $1,100.00 101,100 17.00% view
P 2008-11-13 2008-11-17 10:16:47 DISCOVERY LABORATORIES INC /DE/ DSCO LOPEZ DAVID L officer (Executive VP & Legal Counsel) 5,000 $1.03 $5,150.00 69,482 17.48% view
P 2008-11-17 2008-11-17 10:16:13 DISCOVERY LABORATORIES INC /DE/ DSCO CAPETOLA ROBERT J CEO 10,000 $1.04 $10,450.00 446,025 16.75% view
P 2008-11-17 2008-11-17 10:02:43 DISCOVERY LABORATORIES INC /DE/ DSCO CAPETOLA ROBERT J CEO 40,000 $1.01 $40,400.00 436,025 20.79% view
Recent WINT News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:59:51 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/09/2024 12:41:34 PM
- Windtree Therapeutics Regains Compliance with Nasdaq • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Windtree Therapeutics Announces Reverse Stock Split • GlobeNewswire Inc. • 04/18/2024 12:00:00 PM
- Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates • GlobeNewswire Inc. • 04/17/2024 12:00:00 PM
- Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing • GlobeNewswire Inc. • 04/08/2024 08:48:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 10:07:43 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/14/2024 10:23:27 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:30:23 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:15:54 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 09:40:42 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/01/2024 10:26:23 PM
- Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research • GlobeNewswire Inc. • 02/01/2024 01:00:00 PM
- Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives • InvestorsHub NewsWire • 01/31/2024 01:40:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 01:00:12 PM
- Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives • GlobeNewswire Inc. • 01/31/2024 01:00:00 PM
- Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company • InvestorsHub NewsWire • 01/25/2024 02:04:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 01:34:03 PM
- Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company • GlobeNewswire Inc. • 01/25/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 09:45:14 PM
- Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region • GlobeNewswire Inc. • 01/17/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 12:56:06 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/16/2024 09:16:06 PM
- Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator • GlobeNewswire Inc. • 01/02/2024 09:05:00 PM
- Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock • GlobeNewswire Inc. • 12/18/2023 01:00:00 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM